We are excited to announce Perspective Therapeutics is set to join the Russell 3000 Index effective July 1st. Find more information at https://lnkd.in/e7iTEG4A
Perspective Therapeutics
Pharmaceutical Manufacturing
Game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.
About us
We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.
- Website
-
https://perspectivetherapeutics.com
External link for Perspective Therapeutics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Type
- Public Company
- Founded
- 2023
- Specialties
- Oncology, Cancer Treatment, Radiopharmaceuticals, and Imaging Technologies & Diagnostics
Employees at Perspective Therapeutics
Updates
-
Only a few days left before #SNMMI24. Our team will be on the ground in Toronto, as we look forward to engaging with industry leaders and presenting on our pipeline. Check all our presentations at https://lnkd.in/eRU_WGhs #radiopharma #radiopharmaceuticals #cancer #oncology #nuclearmedicine
-
Perspective is presenting at the #SNMMI24 Annual Meeting on June 8-11 in Toronto. The presentations will focus on the company’s sponsored studies of its assets including [212Pb]VMT-α-NET, [212Pb]VMT01 and [203/212Pb]-PSV-359. More details about the presentations can be found via the link -> https://lnkd.in/eRU_WGhs #radiopharma #radiopharmaceuticals #cancer #oncology #nuclearmedicine
-
Tomorrow, Perspective Therapeutics rings the opening bell at the NYSE in recognition of #NationalCancerResearchMonth and its mission to improve the lives of #cancer patients through pioneering proprietary #radiopharmaceuticals to deliver powerful radiation specifically to cancer cells. #oncology #precisionmedicine #nuclearmedicine #NCRM24 #CancerResearchMonth
-
Our first human imaging with [203Pb]PSV359 suggests rapid uptake and sustained retention in multiple cancer types. PSV359 is a novel peptide developed by our in-house discovery team which targets Fibroblast Activation Protein-α (FAP). Imaging was performed by Dr. Ishita Sen’s group at Fortis Memorial Research Institute - India. Further information will be available in upcoming presentations and publications. https://lnkd.in/ePh7Z6Zh #nuclearmedicine #radiopharma #oncology
-
Perspective’s in-house discovery team has developed and optimized peptide PSV359 with potential best-in-class characteristics for targeting FAP – the hot new pan-cancer target everyone is talking about. The peptide shows high uptake and retention in preclinical tumor models of sarcoma, with rapid renal clearance. Further information will be available in upcoming presentations and publications. Follow our progress on socials and the website: https://lnkd.in/ePh7Z6Zh #nuclearmedicine #radiopharma #oncology
-
Introducing PSV359 – a novel FAP-targeting peptide! It is a significant addition to our clinical pipeline as we continue to advance targeted #alphatherapeutics to fight #cancers. Learn more about our pipeline: https://lnkd.in/e3G62Def #nuclearmedicine #radiopharma #oncology
-
Save the date! May 15 – Perspective Therapeutics to provide recent business highlights and report 1Q financial results: https://lnkd.in/ewdpdeJD
-
Did you know - Fibroblast Activation Protein-α (FAP) is a potential game-changer in #cancer therapy? Primarily expressed on tumor stroma cells, FAP represents a promising target across multiple cancer types which might be suitable for therapeutic radiopharmaceuticals. https://lnkd.in/ePh7Z6Zh #nuclearmedicine #radiopharma #oncology
-
Perspective senior management will participate in several upcoming conferences in May. Check our newsroom for more details -> https://lnkd.in/eWS6WvqZ